scispace - formally typeset
F

Frank Stegmeier

Researcher at Massachusetts Institute of Technology

Publications -  13
Citations -  1508

Frank Stegmeier is an academic researcher from Massachusetts Institute of Technology. The author has contributed to research in topics: Cdc14 & Mitotic exit. The author has an hindex of 6, co-authored 13 publications receiving 1473 citations. Previous affiliations of Frank Stegmeier include Novartis.

Papers
More filters
Journal ArticleDOI

Separase, polo kinase, the kinetochore protein Slk19, and Spo12 function in a network that controls Cdc14 localization during early anaphase.

TL;DR: A regulatory network, the FEAR (Cdc fourteen early anaphase release) network that promotes Cdc14 release from the nucleolus during earlyAnaphase is identified and it is proposed that one function of CDC14 released by the Fear network is to stimulate MEN activity.
Journal ArticleDOI

Closing Mitosis: The Functions of the Cdc14 Phosphatase and Its Regulation

TL;DR: The functions of Cdc14 are reviewed and how this phosphatase is regulated to accomplish the coupling of mitotic processes.
Journal ArticleDOI

Cdc14 and condensin control the dissolution of cohesin-independent chromosome linkages at repeated DNA.

TL;DR: It is proposed that Cdc14 released by the FEAR network mediates the partitioning of rDNA by facilitating the localization of condensin thereto and ensures that exit from mitosis is coupled to the completion of chromosome segregation.
Journal ArticleDOI

The Role of the Polo Kinase Cdc5 in Controlling Cdc14 Localization

TL;DR: This work finds that overexpression of CDC5 led to Cdc14 release from the nucleolus in S phase-arrested cells, which correlated with the appearance of phosphorylated forms of CDC14 and Cfi1/Net1.
Journal ArticleDOI

Maintenance of adenomatous polyposis coli (APC)-mutant colorectal cancer is dependent on Wnt/β-catenin signaling

TL;DR: It is shown that active Wnt/β-catenin signaling is required for maintenance of colorectal tumor xenografts harboring APC mutations and this results support efforts to treat human coloreCTal cancer by pharmacological inhibition of the Wnt /β- catenin pathway.